ethyl 4-chloroacetamido-N-(3,4-dichlorobenzyl)indole-2-carboxylate | 288067-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 4-chloroacetamido-N-(3,4-dichlorobenzyl)indole-2-carboxylate
• 英文别名: ethyl 4-[(2-chloroacetyl)amino]-1-[(3,4-dichlorophenyl)methyl]indole-2-carboxylate
• CAS: 288067-67-4
• 化学式: C₂₀H₁₇Cl₃N₂O₃
• 分子量: 439.726
• InChiKey: RLGKRLOZJDTTOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  60.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-chloroacetamido-N-(3,4-dichlorobenzyl)indole-2-carboxylate 、 甘氨酸甲酯盐酸盐 、 三乙胺 在 水 、 乙酸乙酯 、 magnesium sulfate 作用下， 以 1-methoxyethanol 为溶剂， 反应 6.0h， 以to give the product, ethyl 4-[(N-(methoxycarbonylmethyl)glycyl)amino]-N-(3,4-dichlorobenzyl)indole-2-carboxylate的产率得到ethyl 4-[(N-(methoxycarbonylmethyl)-glycyl)amino]-N-(3,4-dichlorobenzyl)indole-2-carboxylate
  参考文献：
  名称：

  Anti-inflammatory indole derivatives

  摘要：

  公式（I）的治疗化合物，其中X为CH2或SO2; R1为可选取代的芳基或杂环基; R2和R3为各种指定的基团，R4为NHCOR15，NHSO2R15或OCONR16R17基团，其中R15，R16和R17为各种定义的基团; R5，R6和R7独立选择氢，功能团或可选取代的烃基团或可选取代的杂环基团; 此外，当R4为NHCOR15时，R15为取代烷基，可选取代芳基或可选取代杂环基; 这些化合物和组合物在治疗由MCP-1（单核细胞趋化因子-1）或RANTES（活化调节，正常T细胞表达和分泌）介导的疾病，如炎症性疾病中有用。其中还包括含有这些化合物的制药组合物。

  公开号：

  US06911465B1
• 作为产物：
  描述：

  氯乙酰氯 、 Ethyl 4-amino-N-(3,4-dichlorobenzyl)indole-2-carboxylate 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以65%的产率得到ethyl 4-chloroacetamido-N-(3,4-dichlorobenzyl)indole-2-carboxylate
  参考文献：
  名称：

  ANTI-IMFLAMMATORY INDOLE DERIVATIVES

  摘要：

  公开号：

  EP1159269B1

文献信息

• US6911465B1
  申请人：——

  公开号：US6911465B1

  公开（公告）日：2005-06-28
• [EN] ANTI-INFLAMMATORY INDOLE DERIVATIVES<br/>[FR] DERIVES D'INDOLE ANTI-INFLAMMATOIRES
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000046195A1

  公开（公告）日：2000-08-10

  Therapeutic compounds of formula (I) wherein X is CH2 or SO2; R1 is an optionally substituted aryl or heteroaryl ring; R?2 and R3¿ are various specified groups, R4 is a group NHCOR15, NHSO¿2R?15 or OCONR16R17 where R15 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl and R?16 and R17¿ are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R?16 or R17¿ is other than hydrogen, or R?16 and R17¿ together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and R?5, R6 and R7¿ are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R4 is a group NHCOR15, R15 is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by monocyte chemoattractant protein-l or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.
• ANTI-IMFLAMMATORY INDOLE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1159269B1

  公开（公告）日：2003-03-26
• Anti-inflammatory indole derivatives
  申请人：Faull W. Allan

  公开号：US20050026975A1

  公开（公告）日：2005-02-03

  Therapeutic compounds of formula (I) wherein X is CH 2 or SO 2 ; R 1 is an optionally substituted aryl or heteroaryl ring; R 2 and R 3 are various specified groups, R 4 is a group NHCOR 15 , NHSO 2 R 15 or OCONR 16 R 17 where R 15 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl and R 16 and R 17 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted aryl and optionally substituted heteroaryl, with the proviso that at least one of R 16 or R 17 is other than hydrogen, or R 16 and R 17 together with the nitrogen atom to which they are attached from an optionally substituted heterocyclic ring which optionally contains further heteroatoms; and R 5 , R 6 and R 7 are independently selected from hydrogen, a functional group or an optionally substituted hydrocarbyl groups or optionally substituted heterocyclic groups; and further provided that when R 4 is a group NHCOR 15 , R 15 is substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.

  式(I)的治疗化合物，其中X为CH2或SO2；R1为可选取代的芳基或杂环芳基环；R2和R3为各种指定的基团，R4为NHCOR15，NHSO2R15或OCONR16R17基团，其中R15为可选取代的烷基、可选取代的芳基或可选取代的杂环芳基，R16和R17分别选择自氢、可选取代的烷基、可选取代的芳基和可选取代的杂环芳基，但至少其中之一为非氢，或R16和R17连同它们所连接的氮原子可形成可选取代的杂环环，该环还可包含进一步的杂原子；以及R5、R6和R7分别选择自氢、功能基或可选取代的碳氢基团或可选取代的杂环基团；此外，当R4为NHCOR15基团时，R15为取代的烷基、可选取代的芳基或可选取代的杂环芳基。还描述了和声明了含有这些化合物的药物组合物。这些化合物和组合物在治疗由单核细胞趋化蛋白-1或RANTES（激活调节、正常T细胞表达和分泌）介导的疾病，如炎症性疾病中非常有用。